Cargando…

Recurrent Vitreomacular Traction in a Patient Treated with Ocriplasmin: A Case Report

INTRODUCTION: To describe a case of recurrent vitreomacular traction and macular edema that appeared both before and after the intravitreal injection of ocriplasmin. CASE REPORT: An 82-year-old monocular man presented with metamorphopsia and reduced vision of 1-week duration. The patient’s general m...

Descripción completa

Detalles Bibliográficos
Autores principales: Katsanos, Andreas, Gorgoli, Konstantina, Asproudis, Ioannis, Stefaniotou, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7886937/
https://www.ncbi.nlm.nih.gov/pubmed/33108639
http://dx.doi.org/10.1007/s40123-020-00316-z
Descripción
Sumario:INTRODUCTION: To describe a case of recurrent vitreomacular traction and macular edema that appeared both before and after the intravitreal injection of ocriplasmin. CASE REPORT: An 82-year-old monocular man presented with metamorphopsia and reduced vision of 1-week duration. The patient’s general medical history was unremarkable. His ophthalmic history was significant for severe ocular trauma in the right eye in childhood that caused phthisis. The left eye had undergone uncomplicated phacoemulsification 3 months earlier and the 1-month postoperative best corrected visual acuity (BCVA) was logarithmic mean angle of resolution (logMAR) 0.0. There was no history of other ocular conditions. At presentation, BCVA was logMAR 0.2 and optical coherence tomography (OCT) revealed the presence of cystoid macular edema caused by vitreomacular traction (VMT). The patient was scheduled for intravitreal ocriplasmin injection. Prior to treatment, the vision improved spontaneously to logMAR 0.1, and no VMT could be detected with spectral domain (SD)-OCT. The ocriplasmin injection was deferred but 3 weeks later the patient presented again with metamorphopsia, while VMT was again evident on SD-OCT. Ocriplasmin was injected and 1 month later the BCVA reached logMAR 0.1 without VMT. However, at 2 months post injection the VMT reappeared and a conservative approach with observation and topical nepafenac administration was decided. At the 3-month post-injection visit there was no VMT. More than 3 years after the ocriplasmin injection there is still no evidence of VMT, the patient is free of metamorphopsia, and his BCVA is logMAR 0.0. CONCLUSION: Separation of consecutive layers of the vitreous cortex (vitreoschisis) may account for recurrent VMT.